Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor

Rajiv Kumar, Timothy J. Price, Carol Beeke, Kunal Jain, Gargi Patel, Rob Padbury, Graeme P. Young, David Roder, Amanda Townsend, Sarwan Bishnoi, Christos S. Karapetis

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear. Patients and Methods The South Australian Clinical Registry for mCRC collects data for patients diagnosed after February 2006. Data from 2502 patients, available on October 22, 2012, were analyzed according to stage at initial diagnosis (SAID) to compare outcomes between metachronous tumors (MTs) (stages I, II, III) and synchronous tumors (STs) (stage IV). Overall survival (OS) was calculated from the date of mCRC diagnosis. Results Patients with ST had more liver-only metastases, and patients with MT had more lung-only, non-lung and non-liver, and non-lung metastases. The median time to recurrence differed significantly according to SAID: stage I, 49.3 mo (n = 29), stage II, 25.2 mo (n = 346) and stage III, 18.4 mo (n = 497). The median OS was longer for patients with MT than for those with ST (19.0 vs.14.9 mo, P =.003). For patients who received any treatment for mCRC, the OS was longer for patients with MT than for those with ST (19.2 vs. 15.3 mo, P =.005). In patients who received only chemotherapy for mCRC, the median OS was longer for patients with MT than for those with ST (15.2 vs. 9.9 mo, P <.0001). No difference in OS between the MT and ST groups for patients who did not receive treatment for mCRC (1.6 vs. 2.6 mo; P =.95). Conclusion Patients with MT have a longer OS than those with ST, independent of treatment. Classification of patients according to whether they have metachronous or synchronous presentation of mCRC is prognostic. These results may add further support for population screening with the aim to reduce de novo metastatic disease.

LanguageEnglish
Pages87-93
Number of pages7
JournalClinical Colorectal Cancer
Volume13
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • Epidemiological
  • Patterns of metastases
  • Patterns of treatment
  • Registry
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Kumar, Rajiv ; Price, Timothy J. ; Beeke, Carol ; Jain, Kunal ; Patel, Gargi ; Padbury, Rob ; Young, Graeme P. ; Roder, David ; Townsend, Amanda ; Bishnoi, Sarwan ; Karapetis, Christos S. / Colorectal cancer survival : An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. In: Clinical Colorectal Cancer. 2014 ; Vol. 13, No. 2. pp. 87-93.
@article{60c21e7ae4b54ff486e72a508b2edde0,
title = "Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor",
abstract = "Background Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear. Patients and Methods The South Australian Clinical Registry for mCRC collects data for patients diagnosed after February 2006. Data from 2502 patients, available on October 22, 2012, were analyzed according to stage at initial diagnosis (SAID) to compare outcomes between metachronous tumors (MTs) (stages I, II, III) and synchronous tumors (STs) (stage IV). Overall survival (OS) was calculated from the date of mCRC diagnosis. Results Patients with ST had more liver-only metastases, and patients with MT had more lung-only, non-lung and non-liver, and non-lung metastases. The median time to recurrence differed significantly according to SAID: stage I, 49.3 mo (n = 29), stage II, 25.2 mo (n = 346) and stage III, 18.4 mo (n = 497). The median OS was longer for patients with MT than for those with ST (19.0 vs.14.9 mo, P =.003). For patients who received any treatment for mCRC, the OS was longer for patients with MT than for those with ST (19.2 vs. 15.3 mo, P =.005). In patients who received only chemotherapy for mCRC, the median OS was longer for patients with MT than for those with ST (15.2 vs. 9.9 mo, P <.0001). No difference in OS between the MT and ST groups for patients who did not receive treatment for mCRC (1.6 vs. 2.6 mo; P =.95). Conclusion Patients with MT have a longer OS than those with ST, independent of treatment. Classification of patients according to whether they have metachronous or synchronous presentation of mCRC is prognostic. These results may add further support for population screening with the aim to reduce de novo metastatic disease.",
keywords = "Epidemiological, Patterns of metastases, Patterns of treatment, Registry, Survival",
author = "Rajiv Kumar and Price, {Timothy J.} and Carol Beeke and Kunal Jain and Gargi Patel and Rob Padbury and Young, {Graeme P.} and David Roder and Amanda Townsend and Sarwan Bishnoi and Karapetis, {Christos S.}",
year = "2014",
doi = "10.1016/j.clcc.2013.11.008",
language = "English",
volume = "13",
pages = "87--93",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "2",

}

Kumar, R, Price, TJ, Beeke, C, Jain, K, Patel, G, Padbury, R, Young, GP, Roder, D, Townsend, A, Bishnoi, S & Karapetis, CS 2014, 'Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor', Clinical Colorectal Cancer, vol. 13, no. 2, pp. 87-93. https://doi.org/10.1016/j.clcc.2013.11.008

Colorectal cancer survival : An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. / Kumar, Rajiv; Price, Timothy J.; Beeke, Carol; Jain, Kunal; Patel, Gargi; Padbury, Rob; Young, Graeme P.; Roder, David; Townsend, Amanda; Bishnoi, Sarwan; Karapetis, Christos S.

In: Clinical Colorectal Cancer, Vol. 13, No. 2, 2014, p. 87-93.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Colorectal cancer survival

T2 - Clinical Colorectal Cancer

AU - Kumar, Rajiv

AU - Price, Timothy J.

AU - Beeke, Carol

AU - Jain, Kunal

AU - Patel, Gargi

AU - Padbury, Rob

AU - Young, Graeme P.

AU - Roder, David

AU - Townsend, Amanda

AU - Bishnoi, Sarwan

AU - Karapetis, Christos S.

PY - 2014

Y1 - 2014

N2 - Background Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear. Patients and Methods The South Australian Clinical Registry for mCRC collects data for patients diagnosed after February 2006. Data from 2502 patients, available on October 22, 2012, were analyzed according to stage at initial diagnosis (SAID) to compare outcomes between metachronous tumors (MTs) (stages I, II, III) and synchronous tumors (STs) (stage IV). Overall survival (OS) was calculated from the date of mCRC diagnosis. Results Patients with ST had more liver-only metastases, and patients with MT had more lung-only, non-lung and non-liver, and non-lung metastases. The median time to recurrence differed significantly according to SAID: stage I, 49.3 mo (n = 29), stage II, 25.2 mo (n = 346) and stage III, 18.4 mo (n = 497). The median OS was longer for patients with MT than for those with ST (19.0 vs.14.9 mo, P =.003). For patients who received any treatment for mCRC, the OS was longer for patients with MT than for those with ST (19.2 vs. 15.3 mo, P =.005). In patients who received only chemotherapy for mCRC, the median OS was longer for patients with MT than for those with ST (15.2 vs. 9.9 mo, P <.0001). No difference in OS between the MT and ST groups for patients who did not receive treatment for mCRC (1.6 vs. 2.6 mo; P =.95). Conclusion Patients with MT have a longer OS than those with ST, independent of treatment. Classification of patients according to whether they have metachronous or synchronous presentation of mCRC is prognostic. These results may add further support for population screening with the aim to reduce de novo metastatic disease.

AB - Background Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear. Patients and Methods The South Australian Clinical Registry for mCRC collects data for patients diagnosed after February 2006. Data from 2502 patients, available on October 22, 2012, were analyzed according to stage at initial diagnosis (SAID) to compare outcomes between metachronous tumors (MTs) (stages I, II, III) and synchronous tumors (STs) (stage IV). Overall survival (OS) was calculated from the date of mCRC diagnosis. Results Patients with ST had more liver-only metastases, and patients with MT had more lung-only, non-lung and non-liver, and non-lung metastases. The median time to recurrence differed significantly according to SAID: stage I, 49.3 mo (n = 29), stage II, 25.2 mo (n = 346) and stage III, 18.4 mo (n = 497). The median OS was longer for patients with MT than for those with ST (19.0 vs.14.9 mo, P =.003). For patients who received any treatment for mCRC, the OS was longer for patients with MT than for those with ST (19.2 vs. 15.3 mo, P =.005). In patients who received only chemotherapy for mCRC, the median OS was longer for patients with MT than for those with ST (15.2 vs. 9.9 mo, P <.0001). No difference in OS between the MT and ST groups for patients who did not receive treatment for mCRC (1.6 vs. 2.6 mo; P =.95). Conclusion Patients with MT have a longer OS than those with ST, independent of treatment. Classification of patients according to whether they have metachronous or synchronous presentation of mCRC is prognostic. These results may add further support for population screening with the aim to reduce de novo metastatic disease.

KW - Epidemiological

KW - Patterns of metastases

KW - Patterns of treatment

KW - Registry

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84900521114&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2013.11.008

DO - 10.1016/j.clcc.2013.11.008

M3 - Article

VL - 13

SP - 87

EP - 93

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -